Efficacy of newly developed platinum complexes against osteosarcoma, bone targeting platinum and proteasome inhibitory platinum.

2014 Fiscal Year Final Research Report

• Project/Area Number: 23592180
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Orthopaedic surgery
• Research Institution: Kanazawa University
• Principal Investigator: YAMAMOTO Norio 金沢大学, 医薬保健学総合研究科, 特任教授 (90332668)
• Project Period (FY): 2011-04-28 – 2015-03-31
• Keywords: 新規プラチナ製剤 / 骨肉腫

Outline of Final Research Achievements

Each compound strongly caused concentration-dependent cytocidal effect. IC50 value of trinuclear compound is superior to cisplatin, and both complexes showed caffeine potentiation. Two novel platinum do not show cross resistance to cisplatin. Apoptosis induction and acetylation of histon H2AX were observed. In vivo, 1Pt showed almost same, 3Pt showed stronger antitumor effect compared to cisplatin.Two novel platinum complexes that we developed showed strong ant-tumor effect in osteosarcoma in vitro and in vivo. 3Pt shows superior anti-tumor effect compared to cisplatin. 1Pt shows strong in vivo anti-tumor activity. Apoptosis is induced by DNA double strand break. Novel platinum compounds may overcome cisplatin resistance.

Free Research Field

骨軟部腫瘍